New HRT spray now available in the UK
Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) today announced the UK availability of its new hormone replace therapy (HRT), Lenzetto (estradiol spray), for symptoms of estrogen deficiency in post-menopausal women, at least six months since last menses or surgical menopause, with or without a uterus.
Estradiol spray is applied to the skin and is specifically designed to be delivered as an estrogen spray. Gedeon Richter gained licensing rights to Lenzetto from the product’s developer, Australia’s Acrux (ASX: ACR) in 2013.
Dr Kathrine Scott, medical director at Gedeon Richter UK, said: “Gedeon Richter are very pleased to be able to offer this new HRT, which we hope gives more options to healthcare professionals and women. The availability of estradiol spray means that women who are experiencing menopausal symptoms have a greater variety of potential treatments that could improve their quality of life.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze